BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

BioNxt Solutions Inc. has been granted Patent No. 051510 by the Eurasian Patent Organization for its sublingual drug delivery technology. This patent covers the use of anticancer drugs for treatment in autoimmune and neurodegenerative diseases. The company's lead product, BNT23001, is a sublingual thin-film cladribine formulation for multiple sclerosis. This patent, effective until 2043, protects the product in all eight Eurasian Patent Organization member states, which have a combined population of over 200 million.

The patent marks a milestone in BioNxt's intellectual property strategy, providing the first national-level patent for the company. CEO Hugh Rogers noted that this coincides with a large-mass animal bioequivalence study, potentially leading to further patents and partnerships. Efforts to expand patents in other regions, such as the EU and the US, are underway, seeking to strengthen BioNxt's market position.